Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novozymes A/S    NZYM B   DK0060336014

NOVOZYMES A/S (NZYM B)
My previous session
Most popular
  Report  
Delayed Quote. Delayed  - 01/18 10:59:35 am
299.7 DKK   +0.57%
2018NOVOZYMES A/S : quaterly earnings release
2018NOVOZYMES A/S : half-yearly earnings release
2018European shares recover from seven-day losing streak
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Novozymes A/S : Interim report for the first half of 2018

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/10/2018 | 01:58am EST

Satisfactory first half with 4% organic sales growth

Organic sales growth of +4% in the first half (Q2: +5%): Household Care -1%, Food & Beverages +4%, Bioenergy +14%, Agriculture & Feed +3%, Technical & Pharma -6%. EBIT margin at 28.1%. FCF before acq. DKK 890 million. Net profit growth +5%. Full-year 2018 outlook maintained.

Peder Holk Nielsen, President & CEO of Novozymes: “Overall, I’m satisfied with our performance in the first half year. Bioenergy performed very well, whereas Household Care was softer than expected. Our innovation pipeline is solid, and a stronger commercial and emerging market focus is paying off. We’re launching a new, exciting product for animal health, and both our freshness & hygiene platform for laundry and the new corn inoculant are making good progress. And while uncertainty around global trade and agricultural markets persists, we remain committed to our 2018 guidance.”

Highlights 1H 2018:

  • Organic sales growth of +4% (Q2: +5%) and -4% in DKK. USD/DKK decline of 10% in 1H y/y
  • Organic sales growth of +4% (Q2: +5%) and -4% in DKK. USD/DKK decline of 10% in 1H y/y
  • Growth in Food & Beverages and Agriculture & Feed; Bioenergy particularly strong
  • Household Care softer than expected, as Q2 was impacted by customers’ region-specific challenges in Brazil and North America
  • +7% organic sales growth in emerging markets; developed markets +2%
  • Good ramp-up of recent product launches. Freshness & hygiene platform in Household Care developing according to plan with first commercial product available in stores in the Philippines. Preparation of BioAg’s B-360 corn inoculant in Q2 after regulatory approval in Q1
  • EBIT margin of 28.1% (1H 2017: 27.1%; 28.5% excluding reorganization costs) impacted by currency headwind, increasing input costs and lower deferred income
  • Net profit growth of +5% from lower financial costs and lower effective tax rate
  • Free cash flow before acquisitions at DKK 890 million; CAPEX at DKK 635 million

Full-year 2018 outlook maintained on all parameters: Organic sales growth of 4-6% with continuing high uncertainty around global trade and agricultural markets. Household Care still expected to grow organically for the full year, supported by the freshness & hygiene platform.


Attachment

  • 2018_47_Q22018_CompanyAnnouncement_FINAL_EN

© OMX, source OMX

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVOZYMES A/S
01/17ATTIS INDUSTRIES : Novozymes and Attis to Collaborate on Biorefinery Technologie..
AQ
01/17ATTIS INDUSTRIES : Announces Collaboration with Novozymes to Provide Bio-technol..
AQ
2018NOVOZYMES A/S : Proposal of candidates to the Board of Directors
AQ
2018NOVOZYMES A/S : Transactions under Novozymes' stock buyback program
AQ
2018NOVOZYMES A/S : Transactions under Novozymes' stock buyback program
AQ
2018NOVOZYMES A/S : Transactions under Novozymes' stock buyback program
AQ
2018NOVOZYMES A/S : Transactions under Novozymes' stock buyback program
PU
2018NOVOZYMES A/S : Transaktioner i forbindelse med Novozymes' aktietilbagekøbsprogr..
PU
2018NOVOZYMES A/S : Transactions under Novozymes' stock buyback program
AQ
2018NOVOZYMES A/S : Interim report for the first nine months of 2018
AQ
More news
Financials (DKK)
Sales 2018 14 490 M
EBIT 2018 4 087 M
Net income 2018 3 215 M
Debt 2018 2 450 M
Yield 2018 1,66%
P/E ratio 2018 27,23
P/E ratio 2019 25,17
EV / Sales 2018 5,20x
EV / Sales 2019 4,94x
Capitalization 72 904 M
Chart NOVOZYMES A/S
Duration : Period :
Novozymes A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVOZYMES A/S
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 17
Average target price 324  DKK
Spread / Average Target 8,1%
EPS Revisions
Managers
NameTitle
Peder Holk Nielsen President & Chief Executive Officer
Jørgen Buhl Rasmussen Chairman
Thomas Videbaek COO, Executive VP-Research, Innovation & Supply
Prisca Havranek-Kosicek Chief Financial Officer & Executive Vice President
Carl Erik Mathias Uhlén Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVOZYMES A/S3.03%11 100
SAUDI BASIC INDUSTRIES CORPORATION SJSC--.--%98 078
AIR LIQUIDE-2.67%51 490
LYONDELLBASELL INDUSTRIES5.65%33 708
SHIN-ETSU CHEMICAL CO LTD3.81%33 292
GIVAUDAN7.29%22 636